Vor Biopharma Inc.
VORHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Vor Biopharma Inc. (VOR) is listed under Biotechnology. Valued at $1.48B, VOR is a small-cap name in its sector. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Market Cap
$1.48B
Beta
1.72
P/E (TTM)
0.14
P/E (Fwd)
-6.58
EPS (TTM)
$180.69
EPS (Fwd)
$-3.81
ROE
—
ROA
-21.4%
Cash
$466.1M
Total Debt
$2.9M
Free CF
-$79.5M
52W Change
-30.4%
Annual Financials
Cash vs Debt
Where VOR stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, VOR finished 46.10% above its 150-day moving average ($16.14) and 55.13% above its 200-day moving average ($15.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VOR overbought or oversold?
At the August 20, 2026 close, VOR's RSI(14) was 63.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $466.1M in cash comfortably exceeding the $2.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$79.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
A beta of 1.72 means VOR is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vor Biopharma Inc. and its sector.